• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

有内生殖器恶性肿瘤病史女性的激素替代疗法。

Hormonal replacement therapy in women with a history of internal genital organ malignancy.

作者信息

Brzozowska Maria, Lewinski Andrzej

机构信息

Department of Endocrinology and Metabolic Diseases, Medical University, Lodz, Poland Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.

出版信息

Prz Menopauzalny. 2021 Apr;20(1):34-39. doi: 10.5114/pm.2021.104572. Epub 2021 Mar 18.

DOI:10.5114/pm.2021.104572
PMID:33935618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077805/
Abstract

Sudden cessation of ovary activity as a result of bilateral oophorectomy or chemo- or radiotherapy in premenopausal women is linked with more serious consequences that bear no comparison to natural menopause - to name just a few: higher rate of mortality, higher rate of colorectal and lung cancer, circulatory system diseases, cognitive disorders, Parkinson's disease, psychological disorders, osteoporosis, and sexual disorders. The prolonged period of estrogens deficit in premenopausal age is connected with worsened quality of life. The progress in oncological care means that in many malignant diseases, also in the case of gynaecological malignancies, the percentage of survivors increases. This makes improving the quality of life more and more important. The purpose of this review is to establish, based on EBM data, the answer to whether replacement hormonal therapy, being the most effective treatment of menopause symptoms, can be recommended for women who have undergone bilateral oophorectomy because of gynaecological cancer. On the basis of collected data, derived from meta-analysis, and studies which have been published within the last 20 years, it seems that the use of the appropriate type of hormonal replacement therapy (HRT) in properly selected gynaecological cancer survivors (epithelial ovarian cancer - EOC, endometrial cancer, squamous cell carcinoma of the cervix) is safe and effective. It seems that benefits connected with better quality of life that stem from the use of appropriate HRT in gynaecological cancer survivors predominate the unfounded fear of disease recurrence in selected patients' groups.

摘要

绝经前女性因双侧卵巢切除术或放化疗导致卵巢活动突然停止,会带来比自然绝经更严重的后果,仅举几例:死亡率更高、结直肠癌和肺癌发病率更高、循环系统疾病、认知障碍、帕金森病、心理障碍、骨质疏松症和性功能障碍。绝经前雌激素缺乏的延长与生活质量下降有关。肿瘤护理的进展意味着在许多恶性疾病中,包括妇科恶性肿瘤,幸存者的比例增加。这使得提高生活质量变得越来越重要。本综述的目的是基于循证医学数据,确定对于因妇科癌症接受双侧卵巢切除术的女性,作为治疗更年期症状最有效方法的激素替代疗法是否可以推荐。根据从荟萃分析以及过去20年发表的研究中收集的数据,似乎在适当选择的妇科癌症幸存者(上皮性卵巢癌-EOC、子宫内膜癌、宫颈鳞状细胞癌)中使用适当类型的激素替代疗法(HRT)是安全有效的。似乎在妇科癌症幸存者中使用适当的HRT所带来的生活质量改善的益处,在特定患者群体中超过了对疾病复发的无端恐惧。

相似文献

1
Hormonal replacement therapy in women with a history of internal genital organ malignancy.有内生殖器恶性肿瘤病史女性的激素替代疗法。
Prz Menopauzalny. 2021 Apr;20(1):34-39. doi: 10.5114/pm.2021.104572. Epub 2021 Mar 18.
2
Treatment of climacteric symptoms in survivors of gynaecological cancer.妇科癌症幸存者更年期症状的治疗。
Maturitas. 2015 Nov;82(3):296-8. doi: 10.1016/j.maturitas.2015.07.006. Epub 2015 Jul 22.
3
Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.癌症幸存者的激素替代疗法——文献综述。
Pathol Oncol Res. 2020 Jan;26(1):63-78. doi: 10.1007/s12253-018-00569-x. Epub 2019 Jan 8.
4
Hormone replacement therapy for women previously treated for endometrial cancer.曾接受子宫内膜癌治疗的女性的激素替代疗法。
Cochrane Database Syst Rev. 2018 May 15;5(5):CD008830. doi: 10.1002/14651858.CD008830.pub3.
5
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.
6
Hormone replacement therapy after treatment for a gynaecological malignancy.妇科恶性肿瘤治疗后的激素替代疗法。
Curr Opin Obstet Gynecol. 2016 Feb;28(1):32-41. doi: 10.1097/GCO.0000000000000238.
7
Menopause, hormone replacement and gynaecological cancers.更年期、激素替代疗法与妇科癌症。
Menopause Int. 2010 Jun;16(2):89-93. doi: 10.1258/mi.2010.010018.
8
Hormone replacement after gynaecological cancer.妇科癌症后的激素替代治疗。
Maturitas. 2010 Mar;65(3):190-7. doi: 10.1016/j.maturitas.2009.11.017. Epub 2009 Dec 16.
9
Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article.妇科恶性肿瘤后的激素替代疗法:一篇综述文章。
Geburtshilfe Frauenheilkd. 2021 May;81(5):549-554. doi: 10.1055/a-1390-4353. Epub 2021 May 20.
10
Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.预防性输卵管卵巢切除术及绝经前激素替代治疗的应用:科学影响评估报告 66 号,2021 年 10 月:科学影响评估报告 66 号。
BJOG. 2022 Jan;129(1):e16-e34. doi: 10.1111/1471-0528.16896. Epub 2021 Oct 20.

引用本文的文献

1
Hormone replacement therapy in surgical menopause after gynecological malignancies.妇科恶性肿瘤术后手术绝经后的激素替代疗法。
Biomol Biomed. 2025 Mar 7;25(4):751-760. doi: 10.17305/bb.2024.11220.
2
Oral Health Care Among Women in Perimenopause or Menopause: An Integrative Review.围绝经期或绝经后女性的口腔保健:一项综合综述。
J Midwifery Womens Health. 2025 Jan-Feb;70(1):17-31. doi: 10.1111/jmwh.13668. Epub 2024 Jul 24.
3
Impact of Hormone Replacement Therapy on the Overall Survival and Progression Free Survival of Ovarian Cancer Patients: A Systematic Review and Meta-Analysis.激素替代疗法对卵巢癌患者总生存期和无进展生存期的影响:一项系统评价和荟萃分析
Cancers (Basel). 2023 Jan 5;15(2):356. doi: 10.3390/cancers15020356.

本文引用的文献

1
Efficacy of progestin-only treatment for the management of menopausal symptoms: a systematic review.孕激素单独治疗用于管理更年期症状的疗效:系统评价。
Menopause. 2020 Nov 12;28(2):217-224. doi: 10.1097/GME.0000000000001676.
2
European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.欧洲绝经学会(EMAS)和国际妇科肿瘤学会(IGCS)关于妇科癌症后管理绝经的立场声明:关注绝经症状和骨质疏松症。
Maturitas. 2020 Apr;134:56-61. doi: 10.1016/j.maturitas.2020.01.005. Epub 2020 Feb 11.
3
Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review.激素替代疗法是否会影响子宫内膜癌幸存者的预后?系统评价。
Oncology. 2020;98(4):195-201. doi: 10.1159/000505427. Epub 2020 Feb 7.
4
Hormone replacement therapy after surgery for epithelial ovarian cancer.上皮性卵巢癌手术后的激素替代疗法。
Cochrane Database Syst Rev. 2020 Jan 28;1(1):CD012559. doi: 10.1002/14651858.CD012559.pub2.
5
Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis.更年期激素替代疗法与卵巢癌风险:一项荟萃分析。
Front Endocrinol (Lausanne). 2019 Dec 3;10:801. doi: 10.3389/fendo.2019.00801. eCollection 2019.
6
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.ESMO-ESGO 共识会议关于卵巢癌的建议:病理学和分子生物学,早期和晚期,交界性肿瘤和复发性疾病†。
Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062.
7
Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.降低风险的输卵管卵巢切除术(RRSO)后激素替代治疗的安全性:文献系统评价和指南。
Climacteric. 2019 Aug;22(4):352-360. doi: 10.1080/13697137.2019.1582622. Epub 2019 Mar 25.
8
Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.癌症幸存者的激素替代疗法——文献综述。
Pathol Oncol Res. 2020 Jan;26(1):63-78. doi: 10.1007/s12253-018-00569-x. Epub 2019 Jan 8.
9
Gynecologists are afraid of prescribing hormone replacement to endometrial/ovarian cancer survivors despite national guidelines-a survey in Sweden.瑞典的一项调查显示,妇科医生尽管遵循国家指南,但仍害怕为子宫内膜/卵巢癌幸存者开激素替代疗法。
Ups J Med Sci. 2018 Dec;123(4):225-229. doi: 10.1080/03009734.2018.1544597. Epub 2018 Dec 10.
10
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.I 级和 II 级子宫内膜样腺癌中雌激素和孕激素受体的预后意义:激素受体在风险分层中的作用。
J Gynecol Oncol. 2019 Jan;30(1):e13. doi: 10.3802/jgo.2019.30.e13. Epub 2018 Oct 29.